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Background: Infection is highly prevalent and contribute significantly to mortality of 
stroke patients. In addition to the well described robust systemic lymphocytopenia 
and skewed T helper 2 (TH2)-immunity after stroke, emerging experimental evidence 
demonstrate that the development of infection poststroke is attributed by the activation 
of invariant natural killer T (iNKT) cells. In this prospective study, we examined the levels 
of a broad spectrum of inflammatory mediators, the activation status of iNKT cell in the 
blood of patients with various degree of stroke severity, and investigate whether these 
parameters differ in patients who later develop poststroke infections.
Methods and results: We obtained blood from stroke patients and matching controls 
to perform flow cytometry and multiplex measurement of inflammatory mediators. Our 
data suggest a pronounced activation of iNKT cells in stroke patients as compared with 
matched Healthy and Hospital control patients. The magnitude of iNKT activation is 
positively correlated with the severity of stroke, supporting the hypothesis that iNKT cells 
may contribute in the modulation of the host immune response after stroke-associated 
brain injury. In addition, stroke severity is closely correlated with decreased TH1/TH2 
ratio, increased production of interleukin (IL)-10, with infected stroke patients showing 
exacerbated production of IL-10.
conclusion: Stroke triggers a robust and sustained shift in systemic immunity in patients, 
including specific lymphopenia, robust activation of iNKT cells, systemic production of 
IL-10, and a prolonged TH2-skewed immunity, all are potential contributors to severe 
immune suppression seen in patients after stroke. Future studies with large sample size 
will provide potential causality relationship insights.
Keywords: stroke, immune suppression, infection, il-10, inKT cells
inTrODUcTiOn
Ischemic stroke is a common and debilitating cerebrovascular event that is caused by the sudden 
impairment of blood flow to regions of the brain. Up to 65% of stroke patients develop infection (1), 
and more than 30% die as a direct result (2), making infection a highly relevant clinical problem. 
Increased bacterial infections in stroke patients suggest that the immune response, which normally is 
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responsible for eliminating these infections in healthy  individuals, 
is impaired after ischemic brain injury. Emerging evidence now 
indicates that stroke induces profound systemic immune effects 
(3), including severe reductions in the number of circulating 
lymphocytes and altered lymphocyte and monocyte function 
(4, 5). Despite accumulating evidence supporting the notion of 
a stroke-induced peripheral anti-inflammatory state in response 
to the overwhelming cerebral inflammation following stroke (6), 
the molecular mechanisms resulting in systemic immune sup-
pression after stroke in humans have, for the most part, remained 
elusive.
The balance between pro- and anti-inflammatory cytokines 
determines the proficiency of the immunological response and 
has the potential to influence both the fate of the injured brain 
and the threshold to developing complications such as infection. 
In the clinical setting of stroke, the balance between pro- and 
anti-inflammatory cytokines is an important prognostic factor 
(6). Stroke patients were found to present with a rapid increase 
in plasma cytokines resulting in a low ratio of pro-inflammatory 
tumor necrosis factor alpha (TNFα) to anti-inflammatory 
interleukin (IL)-10, preceding the appearance of infection (7). 
This observation supports the hypothesis of stroke-induced 
immunosuppression via a decrease in systemic TH1/TH2 ratio. 
Surprisingly, poststroke T cell priming to an increased IL-4 
expression following mitogenic stimulation was evident in the 
peripheral blood of patients in the post-acute phase of stroke (8). 
Despite this, it is important to note of the timing of this apparent 
immune shift following stroke. Generally, lymphocytes and the 
adaptive immune response could be expected to control infec-
tion 5–7  days after stroke, dysfunction in these cells does not 
explain the observed increase in infection in the first 3 days (9). 
In addition, the development of infection in the mouse model of 
stroke takes only a few hours (10). This difference in the temporal 
development of a TH2-skewed immune response following stroke 
suggests the shift must be orchestrated by mechanisms distinct 
from the conventional adaptive immune response.
In our previous work with an experimental model of ischemic 
stroke, we demonstrated that invariant natural killer T (iNKT) 
cells play an important role in regulating poststroke immu-
nosuppression and infections (10). iNKT cells are a distinct 
lymphocyte lineage that can rapidly produce large quantities 
of both TH1 [interferon gamma (IFNγ), TNFα] and TH2 (IL-4, 
IL-10) cytokines, giving these cells a unique ability to have wide-
ranging roles in the regulation of immunity (11). Despite their 
location in a site remote from the brain, we showed that circulat-
ing iNKT cells and iNKT cells resident in the liver were able to 
rapidly respond to ischemic stroke, and release predominantly 
a TH2-type cytokine IL-10, rendering the host more susceptible 
to bacterial infections (10). This intriguing finding highlighted 
a connection between brain injury sustained following ischemic 
stroke and robust functional impairment of peripheral immune 
cells, in particularly, iNKT cells. In this prospective clinical study, 
we aimed to delineate the systemic immune profile of stroke 
patients over time. Specifically, we conducted a matched cohort 
study to characterize the temporal TH1/TH2 cytokine, chemokine, 
and iNKT cell response in the blood of stroke patients up to 
3  months after stroke onset. In addition, we sought to explore 
whether an association exists between stroke severity with the 
degree of peripheral iNKT cell activation and TH2-skewed sys-
temic immunity.
MaTerials anD MeThODs
study Design
This study was approved by the Conjoint Health Research 
Ethics Board (CHREB) at the University of Calgary. This was a 
prospective cohort study designed to understand the influence 
of stroke on the immune system. We enrolled patients with 
arterial ischemic stroke in the Stroke clinic of the Foothills 
Medical Center. Radiologically confirmed stroke patients with an 
National Institute of Health Stroke Scale (NHISS) score of 4–24 
were enrolled within 24 h of admission after providing written 
informed consent for participation in the study. All of the medica-
tions given to the patients after stroke were documented. Patients 
with known chronic inflammatory or infectious diseases (e.g., 
rheumatoid arthritis, lupus, Crohn’s disease, etc.), cancer, hema-
tological diseases, or severe renal or liver failure, as well as those 
who were under treatment with anti-inflammatory drugs, were 
excluded. In addition, patients with known immunosuppressive 
diseases (including diabetes and human immunodeficiency virus 
infection), a known history of low neutrophil (<2 × 106/mL) or 
lymphocyte (<1 × 106/mL) counts, on immunosuppressive drug, 
asplenia or asplenism, as well as those who were under treatment 
with antibiotics or any forms of adrenergic receptor antagonists, 
were also excluded.
Following consent, blood was collected from each patient into 
lithium-heparin-containing vacutainer tubes (CIE) as soon as 
possible after admission and on days 1, 2, 7 (or discharge, D/C) 
and 90 days thereafter. We also collected demographic (age, sex, 
medical history, medications), admission (presenting illness, 
vital signs, routine laboratory results, initial antimicrobials, 
fluids), microbiology, stroke severity (NIHSS), and physiologic 
(ventilatory support, vasoactive agents, renal function, and liver 
function) information. From the start of enrollment, the stroke 
patients were observed for the development of spontaneous 
infections, including but not limited to pneumonia, urinary tract 
infections, and cellulitis.
Two control groups were included. The first control group 
(Hospital control) consisted of nine patients admitted to the 
clinic for stroke-like symptoms but failed to meet clinical criteria 
for stroke and have no known diseases. The second control group 
(Healthy group) consisted of 10 healthy individuals recruited for 
a one time blood donation. Both controls groups were sex and 
age matched (10-year-spanning categories). The same inclusion 
criteria as stated for stroke patients applied to both groups of 
controls.
sample collection
Sample collection and analyses in the different groups of patients 
and controls were carried out under the same conditions and 
within the same time frame. Following patient consent, blood 
was collected within 24 h of stroke onset to give the “Admission” 
time point, and then at 1, 2, 7 (or at discharge), and 90 days after 
admission. Blood was collected into lithium-heparin-containing 
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vacutainer tubes (CIE) and divided into three portions − (1) rou-
tine hospital microbiology culture, (2) immune cell analysis, and 
(3) measurement of inflammatory mediator levels. Blood collected 
for microbiology was immediately sent to Calgary Laboratory 
Services (CLS) Microbiology at the Foothills Medical Center, 
Canada. Blood collected for immune cell analysis was immediately 
sent to the laboratory for processing and fluorescence-activated 
cell sorting (FACS). Blood collected for measurement of inflam-
matory mediator levels was immediately centrifuged at 1,200 g for 
15 min in a swinging bucket centrifuge. The resultant plasma was 
collected and aliquoted for storage at −80°C until inflammatory 
mediator analyses could be performed.
hospital Microbiology culture analysis
Clinical bacteriological analysis was performed by CLS 
Microbiology at the Foothills Medical Center, Canada. For blood 
culture, venipuncture was the technique of choice for obtaining 
blood. Blood culture bottles (green for aerobic and orange for 
anaerobic) were used for collection. The bottle tops were disin-
fected with 70% isopropanol and allow to dry for 1 min. After 
selecting blood collection site, the site was scrubbed with 70% 
isopropanol for a minimum of 30  s and allowed to dry. Using 
10% PVP Iodine or Chlorhexidine gluconate solution, the site 
was cleansed for 30  s using a circular motion, starting at the 
center of the site and moving outward. The site was allowed to 
dry for a minimum of 1 min. After blood collection, the bottles 
were gently mixed by inversion to prevent clotting. Residual 
iodine was removed from the skin with 70% isopropanol after 
venipuncture. Sputum and urine samples were collected in sterile 
containers. All collection tubes and containers were labeled with 
the required patient identifiers, kept at room temperature, and 
processed within 4 h of collection.
immune cell analysis
Collected blood was processed and analyzed by FACS within 2 h 
of collection. A small aliquot of the blood (10 µL) was used to 
perform cell count with a hemocytometer. The remainder of the 
blood (approximately 3 mL) was diluted at a 1:1 ratio with saline 
and carefully layered onto 5  mL of Lymphoprep (Axis-Shield, 
Norway). Gradients were resolved through centrifugation for 
20 mins at 400 g in a bench-top centrifuge with no brake, after 
which the interface containing the lymphocytes was collected 
and washed in cold FACS wash buffer (FWB; PBS, 2% fetal calf 
serum, 0.5  mM EDTA). For analysis of leukocyte populations, 
single cell suspensions of peripheral blood from subjects were 
stained with PE-conjugated PB57-loaded CD1d-tetramer (NIH 
Tetrameter Facility, Atlanta, GA, USA), PerCP-conjugated anti-
CD3 (OKT3, eBioscience), Alexa Fluor 450-conjugated anti-CD4 
(OKT4, eBioscience), and FITC-conjugated anti-CD69 (FN50, 
eBioscience). All samples were analysed on an Attune acoustic 
focusing cytometer (Applied Biosystems).
Measurement of inflammatory Mediator 
levels
Quantification of the concentrations of inflammatory media-
tors was performed using the validated Luminex bead-based 
multiplexing assay from R&D Systems (Minneapolis, MN, USA) 
according to manufacturer’s instructions (12). Briefly, plasma 
samples were thawed quickly at 37°C, centrifuged at 20,800  g 
at 4°C for 10 min and then stored on ice. Plasma samples were 
diluted as recommended by the manufacturer and a total of 25 µL 
of diluted plasma were distributed to individual wells on a 96-well 
plate each containing capture bead cocktail. The plate was then 
incubated, in the dark, for 2 h at room temperature on a plate 
shaker set at 500 rotations per minute (rpm). Wells were washed 
three times with 100 µL of wash buffer, and then 25 µL of diluted 
biotin antibody cocktail was added. The plate was subsequently 
incubated, in the dark, for 1 h at room temperature on a plate 
shaker set at 500 rpm. Wells were washed three times with 100 µL 
of wash buffer, and 25 µL of diluted Streptavidin-PE was added to 
each well. The plate was incubated for 30 min at room tempera-
ture on a plate shaker set at 500 rpm. Wells were washed three 
times with 100 µL of wash buffer, resuspended in 75 µL of wash 
buffer, and the plate was read using a Luminex 200 apparatus 
(Applied Cytometry Systems, UK). The data were analyzed using 
the StarStation V.2.3 (Applied Cytometry Systems, UK).
statistical analyses
All values were expressed as mean  ±  SEM. Parametric and 
non-parametric statistical tests were used for the analyses. Data 
were compared either by unpaired two-tailed Student’s t-test 
and one-way ANOVA with Bonferroni multiple comparisons 
post hoc test or unpaired two-tailed Mann–Whitney U test and 
Kruskal–Wallis test. Pearson’s correlation coefficient (r) was 
used to measure the strength of linear relationship between two 
variables, with 95% confidence interval expressed in brackets. We 
considered p-values <0.05 statistically significant.
resUlTs
A total of 36 stroke patients were enrolled in the study, 7 of 
whom were unable to be contacted or deceased at the 90 days 
time point. The baseline characteristics and clinical outcomes of 
the 36 enrolled patients and their age-matched 9 Hospital and 10 
Healthy controls were reported previously (13) and detailed here 
in Table 1. We examined the presence and identity of pathogens 
in specimens such as blood, urine, and sputum in a prospective 
manner with strict inclusion/exclusion patient enrollment crite-
ria. In this study, 8 of the 36 patients enrolled (22.2%) showed 
positive cultures in blood, urine, or sputum by day 7 of stroke 
onset. No culturable organisms were found in the blood, urine, or 
sputum at any time point of Healthy and Hospital control patients 
using the same technique. The identity of pathogens found in 
the specimens of the infected stroke patients was examined and 
reported (13). The relatively small patient sample size due to 
strict inclusion/exclusion patient enrollment criteria in this study 
indeed does not represent the population norm, but the infection 
incidence is within the range of those reported (14).
We first examined the circulating white blood cell counts in 
stroke patients compare to their Healthy and Hospital controls. 
There was a significant increase in the number of circulating 
leukocytes in patients with stroke at Admission and up to 7 days 
following stroke onset compared to their Healthy controls 
(Figure  1A). Despite this, stroke patients had a significant but 
TaBle 1 | Baseline characteristics of the enrolled subjects.
characteristics stroke without infection stroke with infection hospital healthy
Number of patients, no. (%) 28 (77.8) 8 (22.2) 0 (0) 0 (0)
Age, years, median (IQR) 65.5 (56.5, 72.5) 76.5 (72.75, 83.5) 71.0 (47.0, 83.0) 63.0 (43.75, 79.5)
Male sex, no. (%) 16 (57.1) 6 (75) 5 (55.6) 5 (50%)
Mortality, no. (%) 2 (7.1) 3 (37.5) 0 (0) 0 (0)
National Institute of Health Stroke  
Scale, median (IQR)
6.5 (4, 10.75) 8 (4.25, 20.5) – –
Localization of infarction, no. (%)
MCA 16 (57.1) 6 (75) – –
ACA 1 (3.6) 0 (0) – –
PCA 3 (10.7) 0 (0) – –
Cerebella 1 (3.6) 0 (0) – –
Pontine/midbrain 4 (14.3) 0 (0) – –
Multiple territories 3 (10.7) 2 (25) – –
Hemispheric, no. (%) 
Left 16 (57.1) 4 (50) – –
Right 8 (28.6) 1 (12.5) – –
Bilateral 0 (0) 2 (25) – –
Stem 3 (10.7) 0 (0) – –
Shower 1 (3.6) 1 (12.5) – –
Infection site, no. (%)
Chest – 2 (25) – –
Urinary tract – 6 (75) – –
Mortality from infection, no. (%)
Chest – 2 (100) – –
Urinary tract – 1 (16.7) – –
The National Institute of Health Stroke Scale is composed of 11 items to use as a tool by clinicians to objectively quantify the stroke impairment.
ACA, anterior cerebral artery; MCA, middle cerebral artery; PCA, posterior cerebral artery; IQR, interquartile range.
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transient reduction in the number of circulating lymphocytes 
at Admission and on day 1 after stroke onset as compared to 
matched Healthy controls (Figure  1B). This reduction was 
contributed by the loss of T lymphocytes (Figure 1C), in both 
CD4+ T cells (Figure 1D) and CD8+ T cells (Figure 1E). Unlike 
the conventional T lymphocyte population, stroke injury did not 
reduce the number of iNKT cells in the blood and this popula-
tion of specialized immune cells also did not decrease in numbers 
during the study period (Figure 1F). Intriguingly, the numbers 
of lymphocytes, T cells, particularly CD8+ T cells were similarly 
decreased in Hospital controls compared with Healthy controls. 
This suggests a non-specific stress response affecting circulating 
lymphocyte numbers in hospitalized patients that is not related 
to the stroke injury or contributing to the host susceptibility to 
infection. Lymphocytopenia is a common finding in hospital 
patients (15), this is in spite of rapid enrollment of this group of 
patients to the study as they waited at the Emergency department. 
Nevertheless, we found lymphocyte counts were equally reduced 
in stroke patients with and without infection and irrespective of 
stroke severity in this study.
We next examined if peripheral iNKT cells are activated in 
stroke patients. Both Healthy and Hospital patient controls 
showed basal iNKT cells activation, whereas stroke patients 
demonstrated an approximately threefold increase of iNKT cell 
activation (Figure 2A). It is important to note that we did not 
stimulate the cells with mitogens, we are reporting the activation 
status of the iNKT cells as they are isolated from the circulating 
blood of the patients. This stroke-induced activation of iNKT 
cells was observed for up to 3 months following the stroke event 
(Figure  2A). The degree of iNKT cell activation at Admission 
in patients with stroke was positively correlated to stroke sever-
ity such that patients with higher NIHSS >  15 at the onset of 
stroke demonstrated significantly greater activation of iNKT 
cells compared to patients presented with NIHSS of less than 15 
(Figure 2B).
To examine the specific effect of stroke on the host systemic 
immune system over time, we measured the plasma levels of 55 
cytokines, chemokines, and other markers of inflammation and 
calculated the average fold changes between stroke patients and 
their matching Hospital controls over the 3 months enrollment 
period. We have chosen to compare the levels of inflammatory 
markers of stroke patients with Hospital controls rather than 
the Healthy cohort to examine stroke-specific response and not 
merely stress associated with hospital admission. In addition, 
we have summarized the results of each inflammatory markers 
in the tabular format instead of showing 55 graphs to provide 
a snapshot summary of temporal changes. The fold changes are 
detailed in Table 2, with the plasma level of inflammation mark-
ers at Admission listed in an ascending order. In addition, we 
have marked the cells in Table 2 with different colors according 
to the amount of fold change relatively to the Hospital control 
group. Red and pink cells denote the level of inflammatory 
marker in the plasma that was lowered in the stroke patients 
compared to Hospital controls by more than 2-fold and 1.5-fold, 
respectively. In contrast, navy and light blue cells denotes the level 
of inflammatory marker in the plasma that was elevated in the 
stroke patients compared to Hospital controls by more than 2 and 
1.5 folds, respectively. Overall, there were a greater number of 
FigUre 1 | The number of circulating invariant natural killer T (inKT) cells unchanged after stroke. The number of circulating white blood cells [WBC; (a)], 
lymphocytes (B), CD3+ T cells (c), CD4+ T cells (D), CD8+ T cells (e), and iNKT cells (F) were quantified in Healthy (n = 10) and Hospital (n = 9) controls as well as 
stroke patients at Admission (n = 36) and 1 day (n = 36), 2 days (n = 36), 7 days (or at discharge, DC; n = 14), and 90 days (n = 27) after stroke onset. Error bars, 
SEM. *p < 0.05, **p < 0.01 vs Healthy controls unpaired two-tailed Student’s t-test. N.S. denotes no statistical significance.
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inflammatory markers that showed twofold or higher increase in 
production after stroke.
We focused our attention on the fold changes of four well-
recognized TH1 (IFNγ, IL-2, IL-12, and TNFα) and TH2 cytokines 
(IL-4, 5, 10, and 13). For each stroke patient, we calculated their 
TH1/TH2 ratio by dividing the sum of the TH1 cytokine fold 
differences by the sum of the TH2 cytokine fold differences. We 
found that stroke significantly reduced the TH1/TH2 ratio in the 
blood of patients compared to their matching Hospital controls 
(Figure  3A; dotted line). In fact, this stroke-induced systemic 
immunological shift toward TH2 was evident throughout the 
observational period, including 3 months after the stroke onset 
TaBle 2 | Fold changes of plasma cytokines and chemokines in stroke 
patients as compared to hospital controls.
admission Day 1 Day 2 Day 7/Dc Day 90
Interleukin 
(IL)-12p40
0.2038 0.3217 0.1675 0.1475 0.3312
IL-6 0.5368 6.7618 0.8140 0.8401 0.3000
IFNα2 0.7338 0.6131 0.6308 0.5549 0.9889
MIG 0.7614 0.6714 0.9917 0.7227 1.0008
IL-16 0.7943 0.7663 0.7629 0.6924 0.9124
IL-3 0.8090 0.6260 0.5930 0.7428 0.5605
β-NGF 0.8315 0.7193 0.8044 0.7851 5.7711
IL-2Rα 0.8383 0.7937 0.7921 0.8028 1.2310
IP-10 0.8512 1.0627 1.4743 0.9660 1.5367
MIP-1β 0.8985 1.2883 1.0267 1.0257 0.9754
IL-8 0.9074 1.3195 1.0028 1.1780 0.9227
GROα 0.9337 1.0779 0.8543 0.9698 1.0296
CTACK 0.9474 0.9358 1.0033 0.9681 1.1286
MCP-1(MCAF) 0.9838 16.2556 0.9966 0.8086 0.8982
TNFβ 1.0135 0.8753 0.8152 0.6442 1.2496
IL-2 1.0324 0.9624 1.0730 1.3649 0.6001
IL-18 1.0660 1.1930 1.0340 1.0645 1.2438
IL-1α 1.0760 0.9523 0.9669 0.8696 1.5388
IL-1rα 1.1559 4.0214 1.6220 1.9585 0.7360
SCF 1.1584 1.1888 1.1956 1.1344 1.5535
PDGF-bb 1.1820 1.1830 1.3627 1.8366 1.1124
Eotaxin 1.1948 1.2337 1.3390 1.4456 1.6774
VEGF 1.2749 1.6210 1.9328 2.1658 1.2426
RANTES 1.2857 1.1759 1.7690 1.4019 1.4282
M-CSF 1.3299 1.5452 1.9018 1.2337 2.1465
IL-7 1.3316 1.6421 1.4309 1.5199 1.6575
MCP-3 1.3568 1.0830 1.2693 0.8602 2.0651
FGF basic 1.4055 1.4048 1.6151 1.8718 1.1152
GM-CSF 1.4679 1.5684 1.4339 1.2278 1.0226
SDF-1α 1.4845 1.4878 1.7933 1.9595 2.2563
sCD40L 1.4899 1.0377 2.1347 1.3364 2.5689
MIP-1α 1.5221 1.5882 1.6945 2.1876 1.1375
IL-33 1.5518 1.5232 1.6622 1.5858 2.2660
IL-17 1.7124 2.1088 2.4253 3.7954 1.2275
IL-17F 1.7802 1.4083 2.0998 1.7855 1.5024
IFNγ 1.8360 2.2328 2.2545 2.4735 2.0963
IL-9 1.9167 2.0734 1.8976 1.8670 1.4314
IL-1β 1.9201 2.2875 1.9894 2.2494 1.7892
IL-4 1.9378 2.5649 2.5050 2.7460 2.6155
TNFα 2.1990 2.9117 2.8939 3.2712 1.6760
TRAIL 2.2086 2.2952 2.6970 2.4267 3.0718
IL-13 2.3548 2.2645 2.0511 2.2400 2.5139
HGF 2.3870 1.4815 1.8309 1.5896 1.1896
IL-25 2.4868 1.7641 3.0086 1.8288 2.2186
G-CSF 2.5166 4.5924 2.8161 3.2957 2.7628
IL-10 2.5599 3.0066 3.1600 3.6470 2.9818
SCGFβ 2.6812 2.5675 2.8742 3.3780 2.0363
IL-5 2.6934 3.1685 3.3711 3.1084 8.9355
MIF 2.6944 1.8942 1.4160 1.4807 0.9236
LIF 2.8741 2.1537 2.8275 1.9227 6.6670
IL-22 2.9674 1.9497 2.9147 1.5633 2.4159
IL-23 3.4442 2.9422 4.7494 2.9133 3.4363
IL-12p70 4.0098 4.5469 5.0610 5.8253 4.7402
IL-21 5.2709 3.2876 6.7876 3.4594 5.3262
IL-31 6.2803 2.8972 5.9301 12.0710 10.9669
Fold change vs hospital control: <0.5, <0.67, >1.5, >2.
FigUre 2 | rapid invariant natural killer T (inKT) cell activation after 
stroke. (a) The expression of CD69 in iNKT cells was quantified in Healthy 
(n = 10) and Hospital (n = 9) controls as well as stroke patients at Admission 
(n = 36) and 1 day (n = 36), 2 days (n = 36), 7 days (or at discharge, DC; 
n = 14), and 90 days (n = 27) after stroke onset. Error bars, SEM. *p < 0.05 vs 
Healthy controls, unpaired two-tailed Student’s t-test. The activation of iNKT 
cells of stroke patients with various National Institute of Health Stroke Scale 
(NIHSS) at Admission was also measured (B). Error bars, SEM. **p < 0.01 
one-way ANOVA with Bonferroni multiple comparisons post hoc test.
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(Figure 3A). Patients with severe strokes (NIHSS > 15) demon-
strated a greater impairment in their systemic immunity as evi-
denced by the significant decrease of TH1/TH2 ratio as compared 
to the other stroke patients in this study (Figure 3B).
Within the group of TH2 cytokines, we found there was a 
significant increase of IL-10 production in patients at stroke onset 
compared to both Healthy and Hospital controls, and this stroke-
induced elevation of IL-10 was observed for up to 3 months fol-
lowing the stroke event (Figure 4A), a trend that is very similar 
to the temporal profile of iNKT cell activation after stroke. We 
cannot confirm the increased peripheral IL-10 level after stroke 
was attributed by iNKT cell activation as that would require flow 
cytometric analysis of intracellular cytokine production of live 
iNKT cells. However, we found a positive correlation between 
plasma levels of IL-10 and iNKT cell activation at stroke onset 
(Figure  4B), suggesting that the production of IL-10 in stroke 
patients is likely to associate with the activation of peripheral 
iNKT cell. In addition, we also examined whether stroke severity 
is a key determinant of IL-10 level in patients. Indeed, there was a 
significant positive correlation between plasma levels of IL-10 and 
stroke severity (Figure 4C), with IL-10 levels in stroke patients 
highest when they were admitted to the hospital with a NIHSS 
above 15 (Figure 4D). We next examined whether plasma levels 
of IL-10 at Admission in stroke patients is a potential predictor 
of infection development. In spite of a relatively small cohort of 
patients, we found stroke patients who later developed infections 
showed significantly higher plasma level of IL-10 within 24 h of 
stroke onset (Figure 4E), this is in spite of NIHSS severity score 
(3, 2, and 2 infected patients with NIHSS subgroups 0 < 5, 5–15, 
and >15, respectively).
DiscUssiOn
Stroke is one of the leading contributors to morbidity and 
mortality worldwide. Despite its recognized debilitating 
neurological deficits, the major cause of death in the post-acute 
phase after stroke is infection (1). These infections have tradi-
tionally been associated with precipitants such as aspiration, 
indwelling catheters, immobility related to severe strokes, or other 
FigUre 3 | stroke-induced systemic shift toward Th2. The plasma cytokine TH1/TH2 ratio of stroke patients at Admission (n = 36) and 1 day (n = 36), 2 days 
(n = 36), 7 days (or at discharge, DC; n = 14), and 90 days (n = 27) after stroke onset was presented in the box and whisker plot (a). The plasma cytokine TH1/TH2 
ratio of stroke patients with various National Institute of Health Stroke Scale at admission was also calculated (B). Dotted line denotes Hospital controls. Error bars, 
SEM. **p < 0.01, one-way ANOVA with Bonferroni multiple comparisons post hoc test.
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FigUre 4 | stroke-induced production of interleukin (il)-10. The plasma levels of IL-10 in Healthy (n = 10) and Hospital (n = 9) controls as well as stroke 
patients at Admission (n = 36) and 1 day (n = 36), 2 days (n = 36), 7 days (or at discharge, DC; n = 14), and 90 days (n = 27) after stroke onset were measured (a). 
Error bars, SEM. **p < 0.01, *p < 0.05 vs Hospital controls, unpaired two-tailed Student’s t-test. Correlation coefficient was calculated between plasma IL-10 levels 
and invariant natural killer T (iNKT) cell activation (B) and National Institute of Health Stroke Scale (NIHSS) (c) at Admission. Pearson’s correlation coefficient (r) with 
95% confidence interval expressed in brackets. Plasma level of IL-10 at Admission was measured in stroke patients with different NIHSS (D). Error bars, SEM. 
*p < 0.05, one-way ANOVA with Kruskal–Wallis test. Plasma level of IL-10 at Admission was measured in stroke patients who later developed poststroke infection 
(e). Error bars, SEM. *p < 0.05 vs no infection, unpaired two-tailed Mann–Whitney U test.
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health co-morbidities. Although such factors may play a role, it 
is now being increasingly recognized that stroke results in the 
impairment of the immune system (3). In our previous work in 
an experimental model of ischemic stroke, we demonstrated that 
stroke alters the function of iNKT cells, which are critical in the 
regulation of antibacterial defense (10). In addition, we found that 
reversing the stroke-induced impairment of iNKT cells restored 
normal function of the immune system and reduced poststroke 
infection, thus providing a novel avenue for limiting the major 
cause of death in stroke patients. To date, there is no information 
on the functional status of human iNKT cells after stroke. This 
knowledge is essential as we progress to develop potential iNKT 
cell-targeting novel agents to limit infection incidence in patients 
with stroke. Therefore, in this study, we performed a temporal 
analysis of iNKT cell activation and cytokine response in the blood 
of stroke patients and examine the association of these responses 
with stroke severity and susceptibility to poststroke infections.
Unlike animal models of stroke where we can control the loca-
tion, duration, and severity of brain injury, clinical stroke studies 
consist of a much more diverse set of patient characteristics and 
stroke parameters. Therefore, variation between patients can mask 
distinctive differences. Often, this patient to patient variability 
can be controlled for by relating values to individual baseline 
data sets. With regards to this study, the inability to prospectively 
enroll patients prior to the stroke event made it impossible to 
gather pre-injury data for patients included in this study. Instead, 
we took the approach to use Hospital controls as a baseline to 
examine immune changes and calculate the fold differences of 
inflammatory mediators in individual stroke patients. Despite 
the relatively small patient sample size, which was likely to be 
limited by strict inclusion/exclusion patient enrollment criteria 
in this pilot prospective study, we demonstrated patients with 
stroke have altered immune response from onset that prolonged 
to 3 months after injury.
We observed a threefold increase in the expression of the acti-
vation marker CD69 in circulating iNKT cells of stroke patients 
compared to both matching Healthy and Hospital controls. These 
data suggest that the iNKT cell activation is specifically mediated 
by the brain injury induced by ischemic stroke and is independent 
of other causes of hospital admission. The magnitude of stroke-
induced activation of iNKT cells was closely associated with the 
severity of stroke injury, with significant elevation reported in 
patients with an NIHSS of 15 or above. We proposed that stroke-
induced activation of iNKT cells mediate an immunosuppressive 
response, via the release of IL-10, and render the patient with 
greater susceptibility to infection. Indeed, iNKT cell activation 
was positively correlated with IL-10 production in patients with 
stroke, and this rapid and sustained elevation of plasma IL-10 was 
exacerbated in patients who developed infections after stroke. 
IL-10 is a pleiotropic cytokine with important immunoregula-
tory functions. Early studies established that IL-10 limits cytokine 
and chemokine production from macrophages and dendritic cells 
during an inflammatory response (16). While localized IL-10 
production in the brain is neuroprotective after stroke (17), we 
and others have found that peripheral levels of IL-10 are closely 
correlated with worsening of stroke outcome (7). Therefore, 
our data support the notion that IL-10 production after stroke 
is critical in the impairment of host antibacterial defense and 
suppression of the systemic immune system, potentially via a 
mechanism that involved the activation of iNKT cells. However, 
the confirmation that the increased peripheral IL-10 level after 
stroke was attributed by iNKT cells will require flow cytometric 
analysis of intracellular cytokine production of live iNKT cells 
in future studies. Nonetheless, the plasma level of IL-10 was 
significantly higher in patients with stroke who later developed 
infections, potentially suggesting the circulatory level of IL-10 at 
stroke onset has the potential to serve as a predictive biomarker 
for poststroke infection.
We examined the levels of a large panel of inflammatory 
mediators, which allow us to observe the systemic shift of 
immune profile after stroke. The stroke-induced shift of immu-
nity toward a TH2-type occurred very rapidly as evidenced by 
significant reduction of TH1/TH2 cytokine ratio in stroke patients 
at the time of hospital admission, and this degree of TH2-skewed 
systemic immunity was dependent on stroke severity. In fact, this 
reduced TH1/TH2 ratio remained significantly lowered compared 
to Hospital controls for the duration of the study, suggesting a 
long-lasting shift of systemic immunity from TH1-type (cell-
mediated “pro-inflammatory”) to a TH2-type (humoral “immu-
nosuppressive”), and that there is limited resetting of immune 
barometer back to homeostasis after stroke. The results from this 
pilot study clearly point to a strong correlation between stroke 
severity, peripheral iNKT cell activation, IL-10 production, 
and severe immunosuppression. Importantly, these poststroke 
immunomodulatory effects continue long after the stroke event 
and are evident in patients after 3 months following the initial 
ischemic stroke onset.
In this study, we did not observe significant activation of circu-
lating iNKT cells in stroke patients who later developed infection. 
Due to the fact that only five patients were analyzed in the severe 
stroke subgroup in this cohort (NIHSS > 15), thus interpretation 
of the current data should be handled with more caution to avoid 
over-interpretation regarding causality of circulating activated 
iNKTs on immune depression and infection in stroke patients. 
This is crucial to provide support to the suggestion that activated 
iNKT cells play a causal role in poststroke immune supression 
and infection after stroke. Nonetheless, our findings suggest that 
the higher activation of iNKT cells was the result of larger strokes, 
and future studies with larger cohort of patients will potentially 
unravel a causality relationship.
Damage to the brain after stroke is now known to be a largely 
immune mediated event not restricted to the cerebral. Stroke-
induced systemic immune changes are believed to be a defensive 
mechanism of the brain with an attempt to lessen further cerebral 
damage; however, this renders the host prone to infections. A 
recent focus has been centered on reducing poststroke infection 
to improve clinical outcomes and patient health. Much attention 
has been drawn to preventive antibiotic treatment, though the 
majority of clinical studies have swayed against prophylactic 
antibiotic administration. Additionally, with the growing 
emergence of antibiotic-resistant pathogens, there is a clear 
need for alternative therapies to reduce infections after stroke. 
Immunomodulation therapies that augment the immune system 
to combat infections is an attractive avenue; however, caution 
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is needed to ensure  further cerebral injury is avoided. Future 
studies with larger patient cohorts should focus on the precise 
mechanisms of immune suppression after stroke in order to 
unveil alternative therapeutic targets to reduce stroke-associated 
infections.
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